Efficacy and Safety of Sorafenib for Advanced Non-Small Cell Lung Cancer: a Meta-analysis of Randomized Controlled Trials

Wang, Weilan; Tang, Zhihui; Xie, Tingting; Xiao, Bingkun; Zhang, Xinyu; Guo, Daihong; Wang, Dongxiao; Pei, Fei; Si, Haiyan; Zhu, Man

doi:10.7314/apjcp.2014.15.14.5691

Cited by 10 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As chemotherapy seems to have reached a plateau in NSCLC treatment, several molecular target agents entered clinical trials in order to try to improve therapeutic outcomes for this disease [94].…”

Section: • • Breast Cancermentioning

confidence: 99%

Sorafenib: 10 years after the first pivotal trial

Gadaleta-Caldarola¹,

Infusino²,

Divella

et al. 2015

Future Oncol.

View full text Add to dashboard Cite

Sorafenib is an oral multikinase inhibitor with anticancer activity against a wide spectrum of cancers. It is currently approved for the treatment of patients with hepatocellular carcinoma, advanced renal cell carcinoma or progressive, locally advanced or metastatic differentiated thyroid carcinoma. In this review, we present a number of studies that investigated the efficacy and safety of sorafenib in these settings. We also discuss the perspectives on the use of this molecule, including the role of sorafenib as comparator for the development of new drugs, the combination of sorafenib with additional therapies (such as transarterial chemoembolization for hepatocellular carcinoma) and the use of this treatment in several other advanced refractory solid tumors.

show abstract

Section: • • Breast Cancermentioning

confidence: 99%

Sorafenib: 10 years after the first pivotal trial

Gadaleta-Caldarola¹,

Infusino²,

Divella

et al. 2015

Future Oncol.

View full text Add to dashboard Cite

show abstract

“…There is not any difference between 2 groups in anemia, leukopenia, diarrhea, and anorexia. Besides rash and hypertension, Wang et al's [ 60 ] study discovered a grade 3 or greater sorafenib-related AEs included fatigue, diarrhea, oral mucositis and hand-foot skin reaction, toxicity profile of thrombocytopenia was not presented in Wang meta. Since our study well balanced basic therapies which might be a potential confounding factor between experimental and control groups, AEs found in this study should be considered in choice of treatment schemes.…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)

Yang¹,

He²,

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…From another perspective, sorafenib was interrogated for treatment of NSCL and showed significant clinical improvement [37,38]. In this regard, it is noteworthy to mention that compound 9b showed profound antineoplastic activity overcoming sorafenib over all tested NSCL cancer cell lines, with IC 50 values of 0.753e1.49 mM.…”

Section: Five-dose Testingmentioning

confidence: 99%